

L12 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:357681 HCAPLUS

DOCUMENT NUMBER: 146:357244

TITLE: Dual variable domain immunoglobulins and multispecific derivatives for treating acute and chronic inflammation, cancer and other diseases

INVENTOR(S): Wu, Chengbin; Ghayur, Tariq; Dixon, Richard W.; Salfeld, Jochen G.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 126pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007071675	A1	20070329	US 2006-507050	20060818
PRIORITY APPLN. INFO.:			US 2005-709911P	P 20050819
			US 2005-732892P	P 20051102

AB The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(CD164; dual variable domain Igs and multispecific derivs.

for treating acute and chronic inflammation, cancer and other diseases)

IT Nervous system, disease

(amyotrophic lateral sclerosis,  $\alpha$ 1-antitrypsin-

deficient; dual variable domain Igs and multispecific derivs. for

treating acute and chronic inflammation, cancer and other diseases)

L3 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1  
 ACCESSION NUMBER: 2006:733581 HCAPLUS  
 DOCUMENT NUMBER: 145:180961  
 TITLE: Use of soluble CD164 variants to treat inflammatory  
 and/or autoimmune disorders  
 INVENTOR(S): Saborio, Gabriela; Power, Christine; Proudfoot, Amanda  
 PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth.  
 Antilles  
 SOURCE: PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006077266	A1	20060727	WO 2006-EP50422	20060124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006207471	A1	20060727	AU 2006-207471	20060124
EP 1841447	A1	20071010	EP 2006-707826	20060124
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
PRIORITY APPLN. INFO.:			EP 2005-100432	A 20050124
			US 2005-655382P	P 20050223
			WO 2006-EP50422	W 20060124

AB The present invention relates to soluble CD164 (sCD164) variants and therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders. The sCD164 variants, comprising the whole or parts of the extracellular domain of human CD164, have an inhibitor effect on the cellular expression and secretion of certain cytokines (interferon  $\gamma$ , interleukins 2, 4, 5, and 10, and tumor necrosis factor  $\alpha$ ) following stimulation of peripheral blood mononuclear cells with agents such as Con A or anti-CD3 and anti-CD28 antibodies. As cytokine release is an event occurring in inflammatory/autoimmune diseases, these sCD164 variants are proposed as therapeutic proteins for prevention or treatment of these diseases. Administration of sCD164 variants significantly decrease cell infiltration in generic models of inflammation and have a pos. effect in a model of Con A-induced hepatitis and in a model of skin inflammation in mice. In addition, sCD164 variants significantly improved various physiol. parameters in models for ulcerative colitis and arthritis in mice.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB . . . or preventing inflammatory or autoimmune disorders. The sCD164 variants, comprising the whole or parts of the extracellular domain of human CD164, have an inhibitor effect on the cellular expression and secretion of certain cytokines (interferon  $\gamma$ , interleukins 2, 4, 5, and 10, and tumor necrosis factor  $\alpha$ ) following stimulation of peripheral blood mononuclear cells with. . .

IT Interferons

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\gamma$ , release in disease models; use of soluble CD164  
variants to treat inflammatory and/or autoimmune disorders)

☐ 3. Document ID: US 20040033493 A1

L4: Entry 3 of 7

File: PGPB

Feb 19, 2004

DOCUMENT-IDENTIFIER: US 20040033493 A1

TITLE: Proteins and nucleic acids encoding same

Detail Description Paragraph:

[0732] The NOV25 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in for example Von Hippel-Lindau (VHL) syndrome, pancreatitis, obesity, Alzheimer's disease, stroke, tuberos sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration, psychiatric disorders, metabolic disorders, fertility, hypogonadism, xerostomia, hyperthyroidism, hypothyroidism, cancer, trauma, tissue degeneration, viral/bacterial/parasitic infections, and/or other diseases and pathologies.

## WEST Search History

DATE: Thursday, October 11, 2007

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L6	Chvatchko-Yolande.in.	28
<input type="checkbox"/>	L5	L3 same EAE	1
<input type="checkbox"/>	L4	L3 same sclerosis	7
<input type="checkbox"/>	L3	NOV25 or CD164 or MGC-24 or endolyn	243
<input type="checkbox"/>	L2	1033401.pn.	8
<input type="checkbox"/>	L1	2002098917.pn.	2

END OF SEARCH HISTORY

=> d his

(FILE 'HOME' ENTERED AT 08:51:33 ON 11 OCT 2007)

FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIX, JAPIO, DISSABS, PASCAL, LIFESCI, CONFSCI' ENTERED AT 08:52:05 ON 11 OCT 2007

L1 330 S (CD164 OR (MGC (A) 24V) OR ENDOLYN)  
L2 18 S L1 (S) (CYTOKINE OR INTERFERON OR (IL?) OR TNF )  
L3 12 DUP REM L2 (6 DUPLICATES REMOVED)  
L4 3131 S SIALOMUCIN  
L5 83 S L4 (S) L1  
L6 122 S L4 AND L1  
L7 33 S L6 (S) (CYTOKINE OR INTERFERON OR (IL?) OR TNF )  
L8 28 S L7 NOT L3  
L9 26 DUP REM L8 (2 DUPLICATES REMOVED)  
L10 12 S L1 AND SCLEROSIS  
L11 171 DUP REM L1 (159 DUPLICATES REMOVED)  
L12 9 DUP REM L10 (3 DU